Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia

Nosocomial pneumonia accounts for almost one-half of all intensive care unit (ICU) mortality and approximately 60% of mortality due to all nosocomial infections. The initial choice of antimicrobial therapy is critical to the clinical outcome of patients with nosocomial pneumonia. Early and aggressive empirical therapy with broad-spectrum agents targeted at the likely pathogens has been associated with a reduction in the ventilator-associated pneumonia (VAP) mortality rate [1‐9]. Awareness of the need for early and appropriate therapy, however, may tempt the clinician to use aggressive empirical therapy at the first sign of infection. Such empirical practices could create a vicious cycle of early and aggressive broad-spectrum antibiotic therapy that may in turn lead to overuse of antibiotics and an increase in antimicrobial resistance.

De-escalation therapy is a method currently used for the management of serious infections, especially in nosocomial pneumonias [2, 10‐17]. Early administration of broad-spectrum antibiotics has been used for treatment to improve appropriate use of empirical therapy. Sequential de-escalation provides maximum benefit for the individual patient and reduces the selection pressure fueling the development of resistance. De-escalation strategies provide clinical balance between using broad-spectrum empirical antimicrobial agents and delaying the initiation of targeted therapy pending the bacteriological culture results. Several studies have shown that de-escalation therapy leads to reduced antibiotic use, shorter duration of therapy and reduced mortality [12, 13, 17].

The most recent VAP treatment guidelines of the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) include recommendations for early, appropriate, broad-spectrum coverage and subsequent de-escalation of antibiotic regimens when possible, based on microbiological culture findings [18].

ATS and IDSA VAP treatment guidelines have suggested that negative lower respiratory tract cultures can be used to discontinue antibiotic therapy in a patient who shows clinical improvement at 48 to 72 hours after the diagnosis of pneumonia and has cultures obtained, in the absence of antibiotic initiation or change, over the previous 72 hours [12, 15, 18]. However, the outcome of de-escalation therapy in patients with negative cultures has not previously been reported.

Studies of de-escalated antimicrobial therapy based on antimicrobial sensitivity testing of microbiological cultures have reported that de-escalation therapy is not possible in patients with negative cultures [14]; that is, the outcome of patients with ICU-acquired pneumonia with negative cultures is unfavorable.

In this study, we evaluated pneumonia-related mortality at day 14 after diagnosis of pneumonia and the risk factors associated with pneumonia-related mortality among patients with ICU-acquired pneumonia that were managed with de-escalation therapy. Furthermore, we focused on the outcome of de-escalation therapy in patients with ICU-acquired pneumonia who had negative cultures.

One hundred thirty-seven patients (mean age, 61.0 ± 16.1 years) were included in the study. Ninety-seven (70.8%) of the patients were male. The patients had a median APACHE II score and modified CPIS of 15.0 ± 5.4 and 8.0 ± 1.5, respectively, at the time of the diagnosis of pneumonia. The median duration of mechanical ventilation and ICU stay before the diagnosis of pneumonia was 6.0 ± 8.9 days and 9.0 ± 20.9 days, respectively. The most frequent ICU admission diagnoses included general postoperative care (35.8%), neurological diseases (24.8%), cardiac diseases (13.1%) and non-ICU-acquired pneumonia (13.1%).

De-escalation therapy was administered in 44 patients (32.1%). Basic demographic and clinical characteristics of the de-escalation and non-de-escalation groups are summarized in Table 1. There were no differences in terms of prior length of ICU stay, prior antibiotic use, use of mechanical ventilation, onset of pneumonia, CCS, APACHE II score, modified CPIS and demographic characteristics between the two groups at the time of diagnosis of ICU-acquired pneumonia.

Appropriate initial antibiotics were received by 32 patients (72.7%) in the de-escalation group and 63 patients (67.7%) in the non-de-escalation group (P = 0.55). Twelve patients in the de-escalation group received initial inappropriate therapy. Three patients did not receive anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) antimicrobial therapy after the identification of MRSA. The therapy of three other patients was altered to include trimethoprim and sulfomethoxazole (TMP/SMX) because they had Sternotrophomonas maltophilia. Two patients showed resistance to the initial antibiotics, and four patients presented with carbapenem-resistant Gram-negative bacilli.

The rate of nonpneumonia infection during treatment of ICU-acquired pneumonia was 31.8% (14 of 44 patients) in the de-escalation group and 23.7% (22 of 93 patients) in the non-de-escalation group (P = 0.31). The median timing of de-escalation was 5.5 days. The mean modified 5-day CPIS and 5-day APACHE II score for all patients are summarized in Table 2. The mean changes in CPIS (from the day of diagnosis of pneumonia to day 5 after the diagnosis of pneumonia) in the de-escalation and non-de-escalation groups were 1.8 ± 1.8 and 1.2 ± 1.6, respectively (P = 0.7).

There were 26 patients (19%) with early ICU-acquired pneumonia (≤4 days following ICU admission) and 111 patients (81%) with late ICU-acquired pneumonia (≥5 days following ICU admission). De-escalation was performed in 9 (34.6%) of 26 patients with early ICU-acquired pneumonia and in 35 (31.5%) of 111 patients with late ICU-acquired pneumonia (P = 0.76). The rate of de-escalation was 36.5% (27 of 74) of the episodes in the medical ICU and 27.0% (17 of 63) in the surgical ICU (P = 0.273).

Of the 137 patients, 117 microbiological pathogens were isolated from 109 patients (79.6%). The initial microbiological identification was based on quantitative information from the TA in 99 cases (73.8%), BAL fluid samples in 5 cases (3.6%), and blood cultures in 3 cases (2.2%). MRSA was the most common pathogen identified (n = 44, 37.6%), followed by Acinetobacter spp. (16.2%), Pseudomonas spp. (15.4%), Klebsiella pneumoniae (10.3%) and S. maltophilia (6.8%).

The most frequently prescribed empirical antibiotic was carbapenem (35%), followed by piperacillin and tazobactam (28.5%), third-generation cephalosporin (22.6%) and cefepime (6.6%). Vancomycin was prescribed in 60 cases (43.8%) as part of a combination regimen. The proportion of cases with appropriate initial antibiotic treatment was 69.3% (95 of 137). A two-agent combination regimen was prescribed in 103 (75.2%) of the total group of patients: 37 in the de-escalation group and 66 in the non-de-escalation group. Monotherapy was prescribed in 32 (23.4%) of all patients: 7 in the de-escalation group and 25 in the non-de-escalation group. Two patients received three antibiotics as empirical therapy. There was no difference between the groups with regard to the use of combination therapy versus monotherapy.

De-escalation therapy in 44 patients was implemented by decreasing the number of antibiotics, the spectrum of antibiotics or both. The number of antibiotics used was decreased for 25 patients (56.8%). In the majority of cases, vancomycin was discontinued when MRSA was not identified. Antibiotics were streamlined to a narrow spectrum in 12 patients (27.3%), whereas 7 patients (15.9%) received de-escalation therapy by decreasing the number as well as the spectrum of antibiotics. Thirty-four of the 137 patients died during a 30-day follow-up period. This represented an overall mortality rate of 24.8% (34 of 137) and a pneumonia-related mortality rate of 10.2% (14 of 137).

Although there was a lower trend for the pneumonia-related mortality rate in the de-escalation group, the difference did not reach statistical significance by day 14 after the diagnosis of ICU-acquired pneumonia (1 (2.3%) of 44 patients versus 10 (10.8%) of 93 patients; P = 0.08) (Figure 1). The pneumonia-related mortality at day 30 was significantly lower in the de-escalation group than in the non-de-escalation group (1 (2.3%) of 44 patients versus 13 (14%) of 93 patients; P = 0.03) (Figure 1). With regard to overall mortality, the de-escalation group had a significantly lower mortality rate than the non-de-escalation group by day 14 (P = 0.04) and by day 30 (P = 0.01).

The pneumonia-related mortality was associated with inadequate empirical antibiotics, non-de-escalation of antibiotics, baseline APACHE II score, 5-day APACHE II score and 5-day CPIS on the basis of univariate analysis. However, only the 5-day APACH E II score and the 5-day CPIS were found to be independent risk factors associated with pneumonia-related mortality and overall mortality (Table 3).

The APACHE II score and the modified CPIS in patients with negative cultures are outlined in Table 4. There was a downward trend in the scores of the patients in the de-escalation group; however, the difference was not statistically significant when compared to the non-de-escalation group. The 30-day pneumonia-related mortality of patients with negative cultures was 0 of 12 (0%) in the de-escalation group and 2 of 16 (12.5%) in the non-de-escalation group. Two patients with negative cultures died on day 3 and day 25, respectively, and they had relatively high APACHE II scores and modified CPIS on day 5.

In this study, the overall de-escalation rate was 32.1% (44 of 137 patients). This proportion increased to 33.7% (32 of 95 patients) when only episodes in which de-escalation was applicable based on antimicrobial susceptibility were considered. The de-escalation rate in this study was lower than the rates in previous studies, in which the de-escalation rates of patients with susceptible pathogens have been reported to be 38% to 51.9% [11, 14]. Alvarenz-Lerma et al.[11] reported that a low de-escalation rate is probably due to a high prevalence of Pseudomonas spp. infection (30.6%), intensive prior use of antibiotics (79.1%) and a larger proportion of late-onset episodes (90.6%). Our study has shown a high incidence of NFGNB cases, including Pseudomonas spp. infection (38.4%) and MRSA infection (37.6%). In addition, a high rate of prior use of antibiotics (93.4%) and a larger proportion of cases with late ICU-acquired pneumonia (81%) were evident in our study. The low de-escalation rate in this study might be due to these factors.

Currently, de-escalation is significantly less frequent in patients with pneumonia who have NFGNB and MRSA. This is because the effectiveness of this approach varies according to local patterns of antibiotic sensitivity. Although Korea has a relatively high prevalence of multiresistant pathogens [25, 26], the de-escalation rate in patients with NFGNB and MRSA in the present study was 34.5%, which is much higher than the 2.7% and 23.1% rates described in previous reports [11, 14].

Among 44 patients in the de-escalation group, 12 patients received inappropriate initial antibiotics. Two patients were changed to narrow-spectrum antibiotics because they showed resistance to initial antibiotics. Four patients who harbored carbapenem-resistant, Gram-negative bacilli received carbapenem or piperacillin and tazobactam, because colistin was not available at that time. Two of these patients died.

Three patients did not receive anti-MRSA antimicrobial agents, even though MRSA infection was identified, because the patients were improving with initial antibiotics. All three patients survived. The MRSA isolated from quantitative tracheal aspirate might not be true pathogens. If the bacteria were merely colonizing pathogens, but not the cause of infection, then the initial antimicrobial therapy would be inappropriate. Quantitative TA allows the identification of pathogens in the great majority (90%) of cases [14]. The antibiotic regimen of three other patients with S. maltophilia was changed to include TMP/SMX and the broad-spectrum antibiotics were switched to narrow-spectrum antibiotics.

The pneumonia-related mortality rate was not significantly different in the de-escalation group compared to the non-de-escalation group at day 14 (P = 0.08). The pneumonia-related mortality and overall mortality at day 30, however, was significantly lower in the de-escalation group (P = 0.03). This finding is consistent with the results reported by Kollef et al.[13]. The pneumonia-related mortality was associated with the 5-day APACHE II score and the 5-day CPIS, even with the adjustment for other factors in addition to the scores at baseline in this study.

The 5-day APACHE II score and the 5-day CPIS were significantly lower in the de-escalation group compared to the non-de-escalation group. The cause of high mortality in the non-de-escalation group was probably related to the high APACHE II score and modified CPIS on day 5, as well as the timing of de-escalation (Table 2). This suggests that de-escalation is effective in patients with ICU-acquired pneumonia who have a more stable severity-of-illness index on days 3 to 5 after the diagnosis of pneumonia. The mean changes in CPIS in the de-escalation group were higher, although this result was statistically insignificant, than in the non-de-escalation group. De-escalation was not performed in patients with a category 3 APACHE II score and CPIS at the time of de-escalation. However, patients in category 1 can be safely de-escalated, and those in category 2 can be considered for de-escalation on the basis of the clinical response of the pneumonia.

De-escalation was carried out in 12 (42.9%) of 28 patients with negative cultures, which resulted in no mortality. Rello et al.[14] did not perform de-escalation in patients with negative cultures because of concern about false-negative cultures and the time to resolution of the febrile illness. Alvarenz-Lerma et al.[11] also did not perform de-escalation in 113 patients with negative cultures, which resulted in a prolonged administration of imipenem. The high portion of patients with negative cultures who did not receive de-escalation was probably influenced by the lack of specific recommendations for de-escalation.

Although our data were collected from a small number of patients with negative cultures, more than 40% of the patients received de-escalation therapy, and all 12 patients survived at day 30 after the diagnosis of pneumonia. The de-escalation group had slightly lower APACHE II score and a lower modified CPIS trend at the time of de-escalation compared to the non-de-escalation group, although both were not statistically significant. Among all patients with negative cultures, two patients in the non-de-escalation group died. They had category 3 APACHE II scores and modified CPIS. If patients with negative cultures are classified in category 1 of the APACHE II score and modified CPIS by day 5, the findings of this study suggest that de-escalation could be considered for such patients with ICU-acquired pneumonia. This is the first study to show that de-escalation therapy in patients with negative cultures is feasible in patients with stable APACHE II scores and modified CPIS.

This study has several limitations. First, because it was a retrospective cohort study, there was no control group. It is ethically impossible to randomize ICU patients because patients with ICU-acquired pneumonia are seriously ill and require complex care. These limitations were minimized by the multivariate analysis. Second, it is difficult to distinguish true infection from colonization. Our respiratory tract specimens were mainly TA (73.8%). It has been noted above that three MRSA isolates in the de-escalation group might not have been true pathogens. It is somewhat confusing to say that therapy was inappropriate because it is possible that MRSA was a colonizer. However, we performed microbiological identification using quantitative methods, and the number of BAL specimens from patients was similar to those described in previous reports. Rello et al.[14] reported that quantitative TA and bronchoscopic samples allowed identification of pathogens in 90% and 93% of episodes, respectively, and there were no differences between the patients diagnosed on the basis of quantitative TA or bronchoscopy with regard to crude mortality and ICU mortality data. Third, there are no standard criteria for initial empirical antibiotic treatments and the timing of de-escalation. However, clinicians usually attempt to follow the currently available ATS and IDSA VAP guidelines for the diagnosis and treatment of pneumonia. Fourth, because of the small number of patients and because it was a single-center study, the results might not be applicable to other groups. Fifth, we measured the modified clinical pulmonary infection score retrospectively. The scores of tracheal secretions were classified as 0 (rare), 1 (abundant) and 2 (abundant and purulent) using ICU nursing records [20]. The ICU nurses recorded the hourly full particles of patients' information. For example, tracheal secretions were recorded as scant whitish, large whitish or large yellowish secretions. We reviewed the nursing records and decided on a score of tracheal secretions.

The patients in the de-escalation group did not show increased mortality compared to those in the non-de-escalation group. The results of this study suggest that de-escalation therapy based on the APACHE II score and the modified CPIS 5 days after the diagnosis of pneumonia can be safely applied with good clinical outcomes for patients with ICU-acquired pneumonia, even in those with negative cultures. Prospective, large studies are needed to evaluate the efficacy of the de-escalation strategy in patients with negative cultures.